| Literature DB >> 20657453 |
Mun Fei Yam1, Vuanghao Lim, Ibrahim Muhammad Salman, Omar Ziad Ameer, Lee Fung Ang, Noersal Rosidah, Muthanna Fawzy Abdulkarim, Ghassan Zuhair Abdullah, Rusliza Basir, Amirin Sadikun, Mohd Zaini Asmawi.
Abstract
The aim of the present study was to verify the anti-inflammatory activity of Orthosiphon stamineus leaf extracts and to identify the active compound(s) contributing to its anti-inflammatory activity using a developed HPLC method. Active chloroform extract of O. stamineus was fractionated into three fractions using a dry flash column chromatography method. These three fractions were investigated for anti-peritoneal capillary permeability, in vitro nitric oxide scavenging activity, anti-inflammatory and nitric oxide (NO) inhibition using carrageenan-induced hind paw edema method. The flavonoid rich chloroform extract fraction (CF2) [containing sinensetin (2.86% w/w), eupatorin (5.05% w/w) and 3'-hydroxy-5,6,7,4'-tetramethoxyflavone (1.101% w/w)], significantly reduced rat hind paw edema, NO and decreased dye leakage to peritoneal cavity at p < 0.05. IC(50) of in vitro NO scavenging of CF2 was 0.3 mg/mL. These results suggest that the anti-inflammatory properties of these CF2 may possibly be due to the presence of flavonoid compounds capable of affecting the NO pathway.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20657453 PMCID: PMC6264410 DOI: 10.3390/molecules15064452
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Effects of chloroform extract fractions of Orthosiphon stamineus leaf on carrageenan-induced rat hind paw edema (n=6).
Figure 2Effects of various doses of chloroform extract fraction 2 of Orthosiphon stamineus leaf on carrageenan-induced rat hind paw edema (n= 6).
Figure 3Effects of Orthosiphon stamineus leaf chloroform extract fractions on peritoneal capillary permeability (n=8).
Figure 4Effect of Orthosiphon stamineus CF2 on nitric oxide (NO) scavenging.
Figure 5Effects of Orthosiphon stamineus leaf chloroform extract fractions on the total amount of nitrite in the plasma (n=6).
Figure 6I) HPLC chromatogram of active sub-fraction CF2. Peaks: (a) TMF, (b) sinensetin, (c) eupatorin; II) HPLC chromatogram of standards. Peaks: (i) TMF, (ii) sinensetin, (iii) eupatorin.
Recovery of sinensetin, eupatorin and TMF.
| Standard | Amount added (mg) | Recovery | |
|---|---|---|---|
| Mean (%) | R.S.D. (%) | ||
| Sinensetin | 0.17 | 101.5 | 0.83 |
| 0.13 | 97.73 | 4.07 | |
| 0.04 | 98.10 | 1.57 | |
| Eupatorin | 0.20 | 97.41 | 3.76 |
| 0.10 | 96.23 | 4.43 | |
| 0.05 | 102.0 | 2.30 | |
| TMF | 0.19 | 97.54 | 2.76 |
| 0.11 | 98.43 | 1.99 | |
| 0.06 | 99.23 | 3.89 | |
Intra-day and inter-day precision for determination of sinensetin, eupatorin and TMF.
| Standard | Concentration (µg/mL) | R.S.D. (%) | |
|---|---|---|---|
| Intraday (n = 5) | Interday (n = 5) | ||
| Sinensetin | 100 | 2.54 | 3.67 |
| 50.0 | 4.35 | 3.10 | |
| 25.0 | 2.13 | 2.67 | |
| 12.5 | 1.27 | 2.17 | |
| 6.25 | 4.52 | 4.09 | |
| Eupatorin | 100 | 4.05 | 4.25 |
| 50.0 | 1.30 | 4.52 | |
| 25.0 | 1.56 | 4.15 | |
| 12.5 | 3.70 | 2.42 | |
| 6.25 | 1.69 | 3.10 | |
| TMF | 100 | 2.43 | 3.12 |
| 33.3 | 1.45 | 3.54 | |
| 11.1 | 3.21 | 3.98 | |
| 3.70 | 1.98 | 2.99 | |
| 1.23 | 3.67 | 3.45 | |
Figure 7Chemical structure of isolated compounds. (a) 5,3’-dihydroxy-6,7,4’-trimethoxy-flavone (eupatorin), (b) 5,6,7,3’,4’-pentamethoxyflavone (sinensetin).